ImmunoCellular Therapeutics, Ltd. announced this morning that it has been granted a U.S. patent relating to its monoclonal antibody therapeutics. Patent No. 7,498,129 entitled “Myeloma Cell and Ovarian Cancer Cell Surface Glycoproteins, Antibodies Thereto, and Uses Thereof,” covers the use of IMUC’s antibodies to measure the effectiveness of the company’s proposed treatment of multiple myeloma and ovarian cancer using the company’s proprietary molecular antibodies.

“This patent provides additional strength to the growing intellectual property position that we are building around our antibody technologies for the detection and the treatment of cancer,” stated Manish Singh, Ph.D., president and chief executive officer of IMUC. “We are actively exploring potential partnering opportunities to enable us to bring these promising technologies through clinical testing and commercialization.”

“I am very encouraged by the preclinical data that we’re observing with these antibodies, most notably their high specificity for binding to multiple myeloma and ovarian cancer, and believe that they could represent a major step forward in the treatment of certain cancers,” commented Cohava Gelber, Ph.D., inventor of the antibody technology and scientific advisor to ImmunoCellular. “With approximately 22,000 new cases of ovarian cancer each year and with more than 63,000 people living with multiple myeloma, both of these cancers would greatly benefit from more effective treatment alternatives.”